UHS — Universal Health Services, Inc.

Sentiment is genuinely split, not quietly bullish or bearish. Q2 2026 (reported 2026-07-27) beat on EPS ($5.98 vs. $5.66 consensus) but management cut full-year adjusted EBITDA guidance to $2.61-$2.72B and adjusted EPS to $22.28-$23.65 the same day, citing behavioral health execution and cost pressure - a classic beat-and-cut that caps upside. The tape shows the ambivalence: as of 2026-09-13 the stock was +19.4% over three months and +3.05% over one week, yet -9.14% over six months and -29% below the 52-week high. Sell-side is equally split: consensus 'Hold' with an average target near $192-$204, RBC trimming to $183 (Sector Perform) in August 2026 while UBS kept a $290 target.

Revenue has been a steady compounder: $3.56B in Q3 2023 to $4.638B in Q2 2026, with YoY growth running ~9-13% through 2024-2025 and decelerating to roughly 8-10% in 2026 (Q1 2026 +9.6%, Q2 2026 +8.3%). Growth is moderating but not breaking. Operating margin is the real story: it expanded from 8.0% in Q3 2023 to a peak of 11.7% in Q2 2025, then rolled over to 11.2% in Q1 2026 and 11.1% in Q2 2026 - the first sustained YoY compression in the window (Q2 2026 operating income of $516.7M on revenue of $4.638B vs. $500.3M on $4.284B a year earlier: revenue +8.3%, operating income +3.3%). Net income growth has effectively flatlined (Q2 2026 $358.4M vs. Q2 2025 $353.2M, +1.5%), and EPS of $5.98 in Q2 2026 compares to $5.74 in Q3 2025, $7.01 in Q4 2025, and $5.65 in Q1 2026 - the $7.01 Q4 2025 print stands out (net income $445.9M, a 9.9% net margin against ~7.7% in adjacent quarters) and looks like a one-off, not a new run rate. Cash flow is the softest leg: Q2 2026 operating cash flow fell to $443.3M from $549.0M a year earlier (-19%), and TTM free cash flow is ~$827M versus ~$901M a year ago. Verdict: a genuine, if modest, inflection down in margin and earnings growth - not a structural revenue break, but no longer an expansion story.

Cheap on every static measure, with one important caveat. As of 2026-09-13: P/E TTM of 7.09x vs. a 5-year average of 12.11x (a ~41% discount); P/S of 0.584 vs. a 5-year average of 0.78 (~25% discount); P/B of 1.388; EV/EBITDA of ~5.5x on FY26 guided EBITDA of $2.61-$2.72B; FCF yield of ~7.8% on TTM FCF of $827M. Forward P/E is 7.6x on the FY26 guidance midpoint of $22.97 and 7.76x on the FY2027 consensus EPS of $22.53. The caveat: the 0.257 PEG ratio is meaningless here - it implies ~28% earnings growth that will not repeat, and FY2026 guidance (~$22.97) is essentially flat versus FY2025 actual (~$22.98), with FY2027 estimates flat again. Also, the 7.09x trailing P/E is flattered by Q4 2025's one-off net income spike. So: cheap, but cheap for a reason - the market is pricing zero earnings growth, and until behavioral health margins stabilize, that multiple is unlikely to re-rate on its own.

The stock is priced for exactly what UHS is currently delivering: revenue growth with no earnings growth. At 7.6x forward EPS against a 12.1x 5-year average trailing P/E, the market is saying management's ~$23 EPS is a plateau, not a base. Two ways this resolves. Bull case: behavioral health labor and Medicaid rate pressure prove cyclical, margins re-stabilize in H2 2026, FY2027 EPS resumes growth, and the multiple re-rates to 9-10x - that is a $200-$225 stock without needing heroic earnings. Bear case: the July 2026 guidance cut was the first of several, EPS drifts to $20 or below, and the 'cheap' 7.6x becomes a 9x on revised numbers - a value trap. Note the credibility problem: Q2 2026 beat by $0.32 and management cut guidance anyway, so the market is now discounting guidance more than beats. The Q3 2026 print on 2026-10-26 is the tell for which path is real.

As of 2026-09-13, RSI(14) stood at 57.36 - neutral, no overbought or oversold signal. Price was +1.24% above the 20-day SMA (~$172.7), +5.73% above the 50-day SMA (~$165.4), but -5.46% below the 200-day SMA (~$184.9). That combination - above the short/intermediate averages, below the long one - is a textbook early-stage recovery inside a still-intact downtrend, confirmed by the +19.4% three-month return against the -9.14% six-month return. Entry-timing implication: this is mid-range, not a gift. A decisive close above the 200-day near $185 would confirm a trend change and likely open the gap toward the $200-$210 area; failure here and a drop back below the 50-day would re-open the $150-$155 zone and retest the $140.08 low. Absent a Q3 catalyst, there is no technical urgency to commit capital.

• Medicaid and ACA reimbursement policy: UHS's behavioral health division generates over half of pre-tax profit and carries heavy Medicaid exposure, so state rate decisions and any federal coverage changes hit margins directly and quickly.
• Healthcare labor cost inflation: wage pressure in nursing and allied staffing is the specific driver management cited in the July 2026 guidance cut; whether it normalizes is the single biggest swing factor in the margin story.
• Interest rates and cost of capital: UHS carries $4.08B of long-term debt against just $138.8M of cash, so refinancing costs and rate expectations feed straight into EPS and free cash flow.
• Sector rotation into managed care and away from facility-based providers: this pressure has compressed provider multiples across the board and is part of why UHS de-rated even as absolute EPS rose.
• Cybersecurity and IT investment requirements: a recurring capex/opex obligation and tail risk for large hospital systems following sector-wide disruptions.

• Q3 2026 earnings after the close on 2026-10-26 - the single most important near-term event, testing whether behavioral health margins are stabilizing, whether the beat-and-cut pattern breaks, and how Talkspace is integrating.
• Talkspace integration (acquisition completed August 2026) - cross-referral economics between virtual and physical behavioral health, and whether management quantifies any revenue or margin contribution.
• FY2026 guidance execution - whether UHS lands inside the revised $2.61-$2.72B EBITDA / $22.28-$23.65 EPS range, or whether another cut (or an upward revision) resets the narrative.
• Capital return at a depressed multiple - the $0.20 quarterly dividend payable 2026-09-15 and any accelerated buyback activity at 7.6x forward earnings would signal management's own view of intrinsic value.
• Medicaid rate updates and state budget cycles - any favorable rate action would be high-leverage to the behavioral health margin recovery case.

• Behavioral health margin erosion proves structural, not cyclical - with over half of pre-tax profit in that segment, a permanent step-down in profitability would invalidate the entire 'cheap on normalized earnings' thesis.
• Earnings stagnation becomes earnings decline: revenue is growing ~8-9% while EPS is flat, and if cost growth keeps outpacing revenue, the current 7.6x forward multiple is not actually cheap.
• Balance-sheet flexibility is limited - $4.08B long-term debt, $138.8M cash, current ratio of 1.116, and a modest 1.5x net leverage that leaves less room to absorb an EBITDA miss than the headline ratios suggest.
• Payer mix and reimbursement risk - Medicaid/ACA exposure and managed care rate negotiations could compress revenue per admission even if volumes hold.
• Talkspace integration and execution risk - a newly acquired virtual-care asset with unproven economics inside a capital-intensive hospital operator.
• Regulatory, litigation, and cyber exposure - behavioral health is a heavily scrutinized segment, and IT disruption risk remains a genuine operational tail risk for a system of this size.

UHS is a genuinely cheap, cash-generative hospital operator that has stopped growing earnings. Revenue is compounding at 8-9%, but operating margin rolled from 11.7% (Q2 2025) to 11.1% (Q2 2026), net income grew just 1.5% YoY last quarter, free cash flow fell 24% YoY, and management cut FY2026 guidance in July 2026. At 7.6x forward EPS, ~5.5x EV/EBITDA, and a 7.8% FCF yield against a 20.5% ROE, the downside is cushioned and the stock is priced for stagnation - but there is no catalyst for multiple expansion until behavioral health margins visibly stabilize. This is a wait-for-the-Q3-print (2026-10-26) situation, not a buy-now; the risk/reward is decent but the timing signal isn't there yet. This is analysis, not personalized financial advice.

Blended forward multiple approach, worked from the FMP data as of 2026-09-13: (1) 8.5x FY2027 consensus EPS of $22.529 = $191.5 - an 8.5x multiple is a ~30% discount to the 5-year average P/E of 12.11x, justified by flat near-term EPS, but well above the current 7.76x forward, which already embeds maximum pessimism; (2) 6.0x FY2026 guided EBITDA midpoint of $2.665B = $15.99B EV, less $3.94B net debt = $12.05B equity, divided by ~60.5M shares = ~$199. A 50/50 blend gives approximately $195, which also implies a ~7.0% FCF yield on TTM free cash flow of $827M - a level a stable, low-growth, modestly levered hospital operator can justify.